QT/QTc evaluation Study in Healthy Japanese Adult Male Subjects

SJP-0008 Phase I -QT/QTc evaluation Study in Healthy Japanese Adult Male Subjects-

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210280

Enrollment

Registered

2021-08-27

Start date

2021-09-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Retinal Artery Occlusion

Interventions

Administration of SJP-0008, placebo and Moxifloxacin and blood collection

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: - Healthy Japanese male - 20-39 years of age at the time of the informed consent - Other protocol-specified inclusion criteria may apply

Exclusion criteria

Exclusion criteria: - History or complications of diseases such as the heart, kidneys, liver, and brain that are considered inappropriate for participation in this clinical trial - History or complications of serious drug allergies or food allergies -Judged by the investigator, etc. to be ineligible for this clinical trial -Other protocol-specified exclusion criteria may apply

Design outcomes

Primary

Measure	Time frame
Prolongation of QT/QTc interval	—

Contacts

Public ContactSenju Laboratory of Ocular Sciences

Senju Pharmaceutical Co., Ltd.

clinical-trial-slos@senju.co.jp+81-78-777-1020

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026